We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

50 hedge funds and large institutions have $30.2M invested in Orchard Therapeutics plc American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less funds holding

Funds holding: 61 → 50 (-11)

22% less capital invested

Capital invested by funds: $38.9M → $30.2M (-$8.66M)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

Holders
50
Holders Change
-11
Holders Change %
-18.03%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
7
Reduced
13
Closed
17
Calls
$10K
Puts
–
Net Calls
+$10K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
Temasek Holdings
Temasek Holdings
Singapore
+$1.87M
2
TCM
Tang Capital Management
California
+$1.13M
3
Renaissance Technologies
Renaissance Technologies
New York
+$661K
4
UOC
UBS O'Connor
Illinois
+$617K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$148K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$3.75M
2
Artisan Partners
Artisan Partners
Wisconsin
-$1.14M
3
SG Americas Securities
SG Americas Securities
New York
-$750K
4
EP
Eversept Partners
New York
-$299K
5
HCA
Harbor Capital Advisors
Illinois
-$168K
Name Holding Trade Value Shares
Change 		Change in
Stake
SEI Investments
26
SEI Investments
Pennsylvania
$20K -$28.3K -5,013 -59%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$15K – – –
BCV
28
Banque Cantonale Vaudoise
Switzerland
$14K – – –
Citadel Advisors
29
Citadel Advisors
Florida
$13K -$73.3K -12,990 -86%
AWM
30
Altium Wealth Management
New York
$13K – – –
CS
31
Cannell & Spears
New York
$13K – – –
Two Sigma Investments
32
Two Sigma Investments
New York
$12K +$11.3K +2,004 New
IIA
33
IPG Investment Advisors
California
$8K – – –
Wells Fargo
34
Wells Fargo
California
$8K – – –
OC
35
Oppenheimer & Co
New York
$8K +$1.41K +250 +22%
HighTower Advisors
36
HighTower Advisors
Illinois
$7K +$6.77K +1,200 New
IAA
37
Ironsides Asset Advisors
North Carolina
$6K -$39 -7 -0.7%
CWM
38
Connecticut Wealth Management
Connecticut
$6K – – –
LG
39
Lane Generational
Massachusetts
$6K – – –
RPCA
40
Running Point Capital Advisors
California
$6K – – –
TRCT
41
Tower Research Capital (TRC)
New York
$4K -$5.47K -970 -57%
APA
42
American Portfolios Advisors
New York
$3.72K – – –
UBS Group
43
UBS Group
Switzerland
$2K -$2.82K -500 -56%
Barclays
44
Barclays
United Kingdom
$1K – – –
CWP
45
Concord Wealth Partners
Virginia
$1K – – –
Osaic Holdings
46
Osaic Holdings
Arizona
$1K – – –
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$1K +$1.13K +200 +20,000%
SG Americas Securities
48
SG Americas Securities
New York
– -$750K -105,279 Closed
EP
49
Eversept Partners
New York
– -$299K -41,958 Closed
HCA
50
Harbor Capital Advisors
Illinois
– -$168K -23,668 Closed
1
2
3

ORTX Hedge Fund Activity: Q2 2022 in Review

50 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q2 2022, worth a combined $30.2M — down 22% from $38.9M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of ORTX and 8 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 7 added.

The largest buyer was Temasek Holdings, adding an estimated $1.87M. The largest seller was RA Capital Management, cutting an estimated $3.75M.

  • 50 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q2 2022, down from 61 in Q1 2022.
  • Funds reported $30.2M of Orchard Therapeutics plc American Depositary Shares stock for Q2 2022, down 22% quarter-over-quarter.
  • 8 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q2 2022 and 17 closed out, a net change of -9 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q2 2022 was Temasek Holdings, an estimated $1.87M added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q2 2022 was RA Capital Management, an estimated $3.75M sold.

Based on aggregated 13F filings for Q2 2022.